We scan new podcasts and send you the top 5 insights daily.
Warma says when ProMIS proposed the larger phase 1b, investors were more interested than in a quick-and-dirty study because they saw the path to skipping phase 2. Pharma partners also responded well to the comprehensive design. He notes the tradeoff is a longer public-company news wait and higher cost, but the pros outweighed cons.
Investor sentiment has fundamentally changed. During the COVID era, investors funded good ideas. Now, they want to de-risk their investments as much as possible, often requiring solid Phase 1 and even compelling Phase 2 data before committing significant capital.
Instead of stopping a trial early for success—which regulators may restrict—a high-confidence early signal provides immense value as business intelligence. This allows sponsors to de-risk and accelerate planning for subsequent phases months earlier, creating millions in value by reducing the gap between Phase 2 and 3.
Biotechs are strategically using Australia's speed to their advantage. By starting a Phase 1 trial in Australia in parallel with a US IND application, they can collect early data from healthy volunteers and a small patient cohort. This data can then be used to strengthen the US filing, potentially justifying a higher starting dose or an improved trial design.
Edward van Vaesel says pharma claims to want early assets but usually gets interested only after Phase 2A de-risking. BGV's original plan was proof-of-concept then partner, yet it now has two Phase 3 companies; the partnering bar has moved meaningfully later overall for biotech startups.
Despite claims of interest in early-stage innovation, big pharma companies typically wait for significant de-risking before acquiring or partnering. BGV's founder observes that real interest usually materializes only after Phase 2A data, forcing venture-backed biotechs to carry assets further than acquirers' stated appetites suggest.
Warma says ProMIS chose a 140-patient, 12-month phase 1b instead of a quick 30-patient biomarker study. By checking safety, target engagement, dose, and clinical signal, they hope to move straight into a registration phase 3, saving years and cost. He says the longer, costlier design was deliberate because short biomarker studies left partners unsure.
Neurocrine mitigates the high risk of its late-stage psychiatry programs, which have uncertain outcomes until Phase 3, by investing in an obesity asset. This program offers the ability to see clear efficacy signals in early Phase 1B trials, providing faster data for decision-making and balancing portfolio risk and cost.
Based on strong Phase 1b data, Celcuity's leadership decided the probability of success was high enough to skip a randomized Phase 2 trial. They concluded that delaying development by three years would be more detrimental than the financial risk of going directly to Phase 3.
The successful, upsized IPOs of several biotechs suggest the market is receptive but cautious. Investors are prioritizing companies with lower-risk propositions, such as those building on validated biological mechanisms or advancing into late-stage trials, over purely speculative, early-stage science.
Unlike big pharma, capital-constrained biotechs can't afford long, expensive trials. MindImmune’s CEO advocates for designing clever Phase 1b studies that use biomarker endpoints to get an early efficacy signal in months, not years, thereby de-risking the program for investors much faster.